ARS-853

ARS-853 is a selective, covalent small molecule inhibitor targeting the KRAS G12C mutant protein. It acts by binding specifically to the GDP-bound (inactive) form of KRAS G12C, locking it in this state and preventing its activation. This inhibition disrupts downstream signaling pathways critical for cancer cell proliferation and survival, particularly in cancers driven by KRAS G12C mutations such as certain lung adenocarcinomas. ARS-853 was one of the first compounds to demonstrate that direct covalent inhibition of mutant KRAS is feasible, providing proof-of-concept for subsequent clinical development of similar agents[2][5][8]. The compound has shown potent activity in preclinical models but remains a research tool rather than a clinically approved drug.